WO2001090252A1 - Gelling composition - Google Patents
Gelling composition Download PDFInfo
- Publication number
- WO2001090252A1 WO2001090252A1 PCT/JP2001/004277 JP0104277W WO0190252A1 WO 2001090252 A1 WO2001090252 A1 WO 2001090252A1 JP 0104277 W JP0104277 W JP 0104277W WO 0190252 A1 WO0190252 A1 WO 0190252A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gelling
- gelation
- polymer
- gel
- component
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 238000001879 gelation Methods 0.000 claims abstract description 185
- 239000003349 gelling agent Substances 0.000 claims abstract description 22
- 239000000499 gel Substances 0.000 claims description 143
- 229920000642 polymer Polymers 0.000 claims description 125
- 239000007864 aqueous solution Substances 0.000 claims description 70
- 230000007704 transition Effects 0.000 claims description 47
- 230000007246 mechanism Effects 0.000 claims description 45
- 239000000126 substance Substances 0.000 claims description 41
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 19
- 230000004962 physiological condition Effects 0.000 claims description 19
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 229940088598 enzyme Drugs 0.000 claims description 16
- 229920000307 polymer substrate Polymers 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000004132 cross linking Methods 0.000 claims description 13
- 108060008539 Transglutaminase Proteins 0.000 claims description 10
- 230000001747 exhibiting effect Effects 0.000 claims description 10
- 102000003601 transglutaminase Human genes 0.000 claims description 10
- 239000003054 catalyst Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 108010049003 Fibrinogen Proteins 0.000 claims description 7
- 102000008946 Fibrinogen Human genes 0.000 claims description 7
- 108090000190 Thrombin Proteins 0.000 claims description 7
- 229940012952 fibrinogen Drugs 0.000 claims description 7
- 230000002427 irreversible effect Effects 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 229960004072 thrombin Drugs 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 5
- 102000003886 Glycoproteins Human genes 0.000 claims description 5
- 108010001535 sulfhydryl oxidase Proteins 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 230000007774 longterm Effects 0.000 abstract description 7
- 239000004615 ingredient Substances 0.000 abstract description 3
- 239000008279 sol Substances 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 238000012360 testing method Methods 0.000 description 20
- 230000002209 hydrophobic effect Effects 0.000 description 18
- 239000000017 hydrogel Substances 0.000 description 17
- 239000000853 adhesive Substances 0.000 description 16
- 230000001070 adhesive effect Effects 0.000 description 16
- 230000036760 body temperature Effects 0.000 description 16
- 239000000178 monomer Substances 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 229920000159 gelatin Polymers 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 108010010803 Gelatin Proteins 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000008273 gelatin Substances 0.000 description 10
- 235000019322 gelatine Nutrition 0.000 description 10
- 235000011852 gelatine desserts Nutrition 0.000 description 10
- -1 polypropylene propylene oxide Polymers 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920001451 polypropylene glycol Polymers 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229940030225 antihemorrhagics Drugs 0.000 description 4
- 239000000227 bioadhesive Substances 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 230000003073 embolic effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000002874 hemostatic agent Substances 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000013081 microcrystal Substances 0.000 description 2
- DFENKTCEEGOWLB-UHFFFAOYSA-N n,n-bis(methylamino)-2-methylidenepentanamide Chemical compound CCCC(=C)C(=O)N(NC)NC DFENKTCEEGOWLB-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- WLPAQAXAZQUXBG-UHFFFAOYSA-N 1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCC1 WLPAQAXAZQUXBG-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010539 anionic addition polymerization reaction Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- NQQRXZOPZBKCNF-UHFFFAOYSA-N but-2-enamide Chemical compound CC=CC(N)=O NQQRXZOPZBKCNF-UHFFFAOYSA-N 0.000 description 1
- 238000010538 cationic polymerization reaction Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 108010002591 epsilon receptor Proteins 0.000 description 1
- JPKNLFVGUZRHOB-YUMQZZPRSA-N epsilon-(gamma-glutamyl)lysine Chemical compound OC(=O)[C@@H](N)CCCCNC(=O)CC[C@H](N)C(O)=O JPKNLFVGUZRHOB-YUMQZZPRSA-N 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 238000005338 heat storage Methods 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- UACSZOWTRIJIFU-UHFFFAOYSA-N hydroxymethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCO UACSZOWTRIJIFU-UHFFFAOYSA-N 0.000 description 1
- GJIDOLBZYSCZRX-UHFFFAOYSA-N hydroxymethyl prop-2-enoate Chemical compound OCOC(=O)C=C GJIDOLBZYSCZRX-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- VQGWOOIHSXNRPW-UHFFFAOYSA-N n-butyl-2-methylprop-2-enamide Chemical compound CCCCNC(=O)C(C)=C VQGWOOIHSXNRPW-UHFFFAOYSA-N 0.000 description 1
- FIBUWQFQYAAXHD-UHFFFAOYSA-N n-cyclopropyl-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NC1CC1 FIBUWQFQYAAXHD-UHFFFAOYSA-N 0.000 description 1
- LCXIFAOALNZGDO-UHFFFAOYSA-N n-cyclopropylprop-2-enamide Chemical compound C=CC(=O)NC1CC1 LCXIFAOALNZGDO-UHFFFAOYSA-N 0.000 description 1
- ZIWDVJPPVMGJGR-UHFFFAOYSA-N n-ethyl-2-methylprop-2-enamide Chemical compound CCNC(=O)C(C)=C ZIWDVJPPVMGJGR-UHFFFAOYSA-N 0.000 description 1
- YPHQUSNPXDGUHL-UHFFFAOYSA-N n-methylprop-2-enamide Chemical compound CNC(=O)C=C YPHQUSNPXDGUHL-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Definitions
- the present invention relates to a gelling composition exhibiting two types of gelling properties which have not been found in the past, and more specifically, comprises at least a polymer component and a gelling agent for gelling the polymer component,
- the present invention relates to a gelling composition which exhibits at least two types of gelation, relatively fast gelation F and relatively slow gelation S, and these gelations satisfy a predetermined relationship.
- the gellable composition of the present invention includes, for example, gelling components having different gelling mechanisms (for example, a gelling component F that gives reversible gelation and a gelling component S that gives irreversible gelation). Are preferably achieved by combining Background art
- the gellable composition of the present invention can be applied without particular limitation to the field where a good balance between short-term adhesive strength and long-term adhesive strength is required.
- the background art relating to the gellable composition of the present invention (especially, the hydrogellable composition) in an embodiment in which gelation and chemical gelation are combined will be described.
- Hydrogels that have been conventionally developed are classified into two types according to the types of cross-linking bonds that constitute the gel.
- a chemical gel whose crosslinks are mainly formed by covalent bonds; and a crosslink mainly formed by physical interactions such as hydrogen bonds, electrostatic bonds, hydrophobic bonds, and van der Waals forces. It is a physical (physical) gel.
- the energy of the above physical bond is usually less than the covalent energy Because of the extremely small physical gel, many physical gels tend to easily undergo a phase transition between the sol state and the gel state due to changes in temperature and concentration.
- thermoreversible hide-mouth gel examples of a type that generates a phase transition between a gel state and a sol state by a temperature change include, for example, gels using gelatin and agar.
- a hydrogel that changes from a gel state to a sol state by heating.
- a hydrogel that changes from a sol state to a gel state by heating.
- thermoreversible hydrogels are usually formed by hydrogen bonding, electrostatic bonding, van der Waalska, microcrystal forming force, etc., and the bonding force of this type of crosslink decreases with increasing temperature. Therefore, these gels change from a gel state to a sol state by heating.
- thermoreversible hydrogels are usually formed by hydrophobic bonds, and this type of hydrophobic bond increases as the temperature rises. Transition to state.
- An example of such a thermoreversible hide-mouth gel is a polymer chain having a cloud point, such as poly-N-isopropylpyranolinoleamide (PNIPAAm) or polypropylene propylene oxide (PPO).
- PNIPAAm poly-N-isopropylpyranolinoleamide
- PPO polypropylene propylene oxide
- Thermoreversible hydrogels in which hydrophilic polymer chains such as polyethylene oxide (PEO) are bonded in a block or graph form have been developed (for example, Japanese Patent Application No. 4-161611). No. 4, Japanese Patent Application No. 5-186967, Japanese Patent Application No. 7-187097, Japanese Patent Application No. 7-187093, etc.).
- the polymer chain having the above cloud point is water-soluble at a temperature lower than the cloud point temperature, but is hydrophobic (water-insoluble) at a temperature higher than the cloud point temperature.
- a temperature higher than the cloud point temperature such a polymer chain gels due to the formation of a crosslinked structure due to hydrophobic bonds between the polymer chains.
- the hydrophobic bonds between the polymer chains are weakened, so that the polymer chains are dissolved in the above-mentioned cross-linked structure and become a sol state (a so-called gelling type at the time of temperature increase). Thermoreversible hydrogel phenomenon).
- the stability of the gel state is usually extremely good, but the surrounding conditions (for example, physiological conditions; 37) ⁇ 39 ° C, pH 7.3-7.6), it is usually very difficult to cause a transition between the sol and gel states. Therefore, when a chemical gel is used for gelling after a certain period of time has passed (for example, an in-vivo adhesive in the medical field), the sol state before forming a cross-linked structure consisting of covalent bonds can It is necessary to place the gel at the injection site by injecting it into the body and causing a chemical reaction in the living body to form the gel.
- An object of the present invention is to solve the above-mentioned drawbacks of the prior art and to realize a gelling property capable of realizing a good balance between a short-term adhesive force and a long-term adhesive force. It is to provide a composition.
- Another object of the present invention is to facilitate application to a predetermined position in a sol state (for example, application in the presence of a fluid in a living body or the like), and to rapidly gel at the predetermined position.
- Another object of the present invention is to provide a gelling composition that can be stably stored at an application position for a long period of time.
- the present inventor has conducted intensive studies and found that the use of a combination of gelling components in which the presence of a crosslinked structure based on fast gelation does not substantially inhibit slow gelation is extremely effective for achieving the above object. I found that.
- the gelling composition of the present invention is based on the above findings, and more specifically,
- a gelling composition comprising at least a polymer component and a gelling agent for gelling the polymer component
- a gelling composition further comprising at least a polymer component and a gelling agent for gelling the polymer component;
- a gelling composition characterized by a gelling composition further comprising at least a polymer component and a gelling agent for gelling the polymer component;
- a gellable composition characterized by exhibiting at least two types of gelation, relatively fast gelling F and relatively slow gelling S, and having different mechanisms of the gelling F and S. Is provided.
- the present invention further comprises a polymer component and a gelling agent for gelling the polymer component.
- a gelling composition characterized by exhibiting at least two types of gelation with irreversible and relatively slow gelation S.
- the cross-linking structure based on the gelling component F that gives relatively fast gelation constituting the composition has a gel that gives relatively slow gelation. Does not substantially inhibit the gelation S, and the presence of the gelling component S does not substantially inhibit the gelling F, so that instantaneous and short-term due to rapid gelation based on the gelling component F It is easy to realize a good balance between the adhesive force and the sustained and stable adhesive force due to the delayed gelation based on the gelling component S.
- the reason that “they do not substantially inhibit each other's gelation” is that the cross-linking structure (or the formation of the cross-linking structure) caused by the “fast gelation” of the gelling component F Gelation in the individual “cells” Since component S can maintain a substantially “liquid” state for an appropriate period of time, even in the crosslinked structure of gelling component F, (substantially affects the presence of the crosslinked structure.
- the gelling component S is capable of “slow gelation” of the gelling component S, and / or the gelling component S that gives the co-existing “slow gelation” in the case of the gelling F is substantially liquid. It is presumed that it is based on "fast gelation” of the gelling component F because it behaves as a fluid, and it is substantially unaffected by the presence of the gelling component S.
- thermoreversible hydrogel of a gelling type at the time of heating when used, the gel is in a sol state at a low temperature and a gel state at a high temperature, and therefore, a biological substance (protein) easily damaged by heating. , Cells, tissue organs, etc.) can be buried in the gel without substantially damaging it.
- a biological substance protein
- Cells, tissue organs, etc. can be buried in the gel without substantially damaging it.
- by lowering the temperature of the biological material buried in the gel it can be easily and easily damaged. It is possible to recover the biological substance from the gel without giving the gel.
- such gels can rapidly undergo a sol-gel transition by changing only the temperature within physiologically acceptable ranges under physiological conditions such as pH, salt type and concentration, etc. it can.
- the heat-reversible hydrogel of the gelling type at the time of temperature rise is frequently placed in contact with a fluid (for example, under physiological conditions such as in a living body in contact with a body fluid).
- a fluid for example, under physiological conditions such as in a living body in contact with a body fluid.
- the gelled thermoreversible hydrogel at the time of temperature rise is used for the purpose of the present invention, for example, an intravascular embolic agent, a hemostatic agent, a bioadhesive, an adhesion inhibitor, a wound covering agent, a drug delivery agent.
- the gel can be administered to a living body in a sol state at a temperature lower than body temperature, and the gel is placed at the injection site to gel immediately at body temperature after administration.
- the in vivo stability of the gel was not as good as described above.
- a simple chemical gel was used for the above-mentioned use of the present invention, and administered to a living body in a sol state before forming a crosslinked structure composed of a covalent bond, and a chemical reaction was performed in the living body.
- the gellable composition of the present invention contains at least a polymer component and a gelling agent for gelling the polymer component, and has at least one of the aforementioned “fast gelation” and “slow gelation”.
- the number of the polymer component and the gelling agent constituting the composition is not particularly limited, and the mechanism of the two types of gelation is not particularly limited.
- the combination of the above components or gelation for example, the following can be suitably used.
- the gelled composition of the present invention exhibits at least two types of gelation, relatively fast gelling F and relatively slow gelling S, and the time (T f) of the gelation F
- the difference from the time of gelation S (T s) is preferably about 30 minutes or more, and more preferably 2 hours or more (particularly 6 hours or more).
- “fast gelation” is caused by physical gelation of the one kind of high molecular component
- “slow gelation” is caused by chemical gelation of the same polymer component. Can be achieved.
- “fast gelation” is achieved by the first chemical gelation of the one type of polymer component, and the same polymer component (provided that the functional group involved in gelation is not functionalized).
- “Slow gelation” can be achieved by chemical gelation of (different).
- “fast gelation” is performed by chemical gelation of the polymer component F, and a chemical gel of another polymer component S (for example, a functional group different from that of the polymer component F) is used.
- “Slow gelation” can be achieved by chemical conversion.
- “fast gelation” is achieved by the combination of the polymer component F and the gelling agent F, and the other polymer component S (eg, the polymer component F and the functional group (Different) "Slow gelation” can be achieved by the combination of one gelling agent S.
- compositions of the present invention may be dissolved or dispersed in various solvents.
- the solvent in this case is not particularly limited, but in an embodiment to be applied to animals (especially humans), the solvent may be an aqueous solvent (that is, water itself or a mixed solvent containing water as a main component). I like it.
- the gelling composition of the present invention can achieve a good balance between “fast gelation” and “slow gelation”. It is preferable that the fast gelling reaction is mainly governed by the gelling mechanism F and the slow gelling reaction is governed mainly by the gelling mechanism S. Preferred embodiments of these gellings are as follows.
- the gelling composition C (showing the gelling mechanism F and the gelling mechanism S) of the present invention exhibits a favorable short-term adhesive force.
- the gel time (T c) is preferably within 15 minutes, more preferably within 10 minutes, and particularly preferably within 5 minutes in the following “fast gelation” measurement.
- the gelation time (T f) when the “gelling mechanism F”, which is one component of the gelling composition C, is used alone is also the same as the “fast gelling” measurement described above. It is preferably within 15 minutes, more preferably within 10 minutes, especially within 5 minutes. In the present invention, it is preferable that the gelling F is not substantially inhibited in the gelling composition C. More specifically, the gelation time (T c) of the gellable composition C and the gelation time (Gc The ratio of T f) (T c ZT f) is preferably 3 or less, more preferably 2 or less (especially 1.5 or less).
- the above-mentioned gelation times T f and T c are both measured under the conditions of “fast gelation measurement J.”
- the conditions of “fast gelation measurement” refer to the gelation mechanism. If F is based on physical gelation, the temperature that is 10 ° C above the sol-gel transition point (ie, 10 ° C above or below the sol-gel transition point) To tell.
- the condition of “fast gelation measurement” refers to the temperature of the site where the gelation should be performed. That is, when used in an animal body, the body temperature of the animal (about 38 ° C for humans), or at room temperature (about 25 ° C) unless the location of application is specified.
- the gelling composition C of the present invention is stirred in a predetermined solvent (distilled water in the case of hydrogel) at a temperature about 10 ° C lower than the sol-gel transition temperature of the physical gelation F. To make an aqueous solution of the gelling composition C with a concentration of about 15%.
- a predetermined solvent distilled water in the case of hydrogel
- the rapid gelation described above is achieved by obtaining a gelling composition C (concentration: about 15%) showing gelling mechanism F and gelling mechanism S, and then about 5 ml of the gel having an inner diameter of about 5 ml. It can be measured by injecting into a 12 ⁇ glass test tube and immersing the test tube in a constant temperature water bath at a temperature of about 38 ° C.
- Gelling composition C (indicating gelling mechanism F and gelling mechanism S) of the present invention Force From the viewpoint of exhibiting its suitable long-term adhesive force, When the slow gelation time (T d) of the gelling composition C has passed, it is preferable that the following “slow gelation” measurement shows the following “resolving inhibition” property.
- the gelling composition C of the present invention is stirred in a predetermined solvent (distilled water in the case of hydrogel) at a temperature about 10 ° C lower than the sol-gel transition temperature of the physical gelation F. To make a solution of gelling composition C with a concentration of about 15%.
- a predetermined solvent distilled water in the case of hydrogel
- gelling mechanism which is one component of the gelling composition C.
- Gel based on ⁇ Nism Z '' is also based on the gelation mechanism S, even if it is placed in a refrigerator at about 6 ° C and left for at least one hour in the same ⁇ slow gelation '' resolving measurement as above. The gel does not sol.
- the gelation time (T s) by itself is preferably 1 hour or more, more preferably 5 hours or more, and particularly preferably 24 hours or more.
- the condition of “slow gelation measurement” means the temperature of the site where the gelation should be performed when the gelation mechanism S is based on chemical gelation. In other words, when used in an animal body, the body temperature of the animal (about 38 ° C for humans), and at room temperature (about 25 ° C) unless the application site is specified. To tell.
- the gelling mechanism giving relatively slow gelation is considered. It is preferred that S is not substantially inhibited by the presence of crosslinks based on the relatively fast gelling mechanism F.
- the gelling composition C of the present invention shows a relatively fast gelling mechanism F and a gelling mechanism S that gives relatively slow gelation
- a gel for testing Composition D (contains at least a component corresponding to the gelling mechanism F and a component D1; the component D1 has only a "slow gelation” ability from the component corresponding to the gelling mechanism S.
- the weight loss behavior in a physiological saline solution at 38 ° C. is as follows.
- the “component D l” For example, it can be achieved by not selectively removing or disabling a component that provides chemical crosslinking (for example, a crosslinking agent or a catalyst such as an enzyme) from a component corresponding to the gelation mechanism S. Can be.
- a component that provides chemical crosslinking for example, a crosslinking agent or a catalyst such as an enzyme
- the ratio (CrZDr) of the weight loss ratio between the gelling composition C and the gelling composition D is preferably 0.4 or less, more preferably 0.2 or less (particularly 0.1 or less).
- gelation mechanism F corresponding to fast gelation and “gelation mechanism S” corresponding to slow gelation are the same. May be different or different. It is preferable that the gelation mechanisms be different from the viewpoint that the balance between these two types of gelation having different rates can be easily achieved. In this case, the rapidity of fast gelation and the stability of slow gelation From the viewpoint of balance, it is preferable that “gelation mechanism F” is physical gelation and “gelation mechanism S” is chemical gelation. Further, it is preferable that the “gelling mechanism F” is reversible gelation and the “gelling mechanism S” is irreversible gelation.
- the gelling component F corresponding to the “gelling mechanism F” of the present invention is preferably a material that undergoes physical gelation and Z or reversible gelation. It is more preferable that the gelling component F has a gelling thermoreversible hind-port gel-forming property upon heating. In this case, it is preferable that the gelation type thermoreversible hydrogel formation upon heating is a physical gel whose cross-links are formed by hydrophobic bonds.
- the gelling component F preferably contains a polymer having a mouth-opening gel-forming property in which the aqueous solution has a sol-gel transition temperature and reversibly shows a sol state at a temperature lower than the transition temperature.
- hydrogel-forming polymer examples include, for example, a polyalkylene oxide block typified by a block copolymer of polypropylene oxide and polyethylene oxide. Copolymer; methylenorelose, hydroxypropynolecellulose and other ethereal diolenolose, chitosan derivatives (K. R. Holme, et al. Mac romolecules, 24, 38, 28 (19) 9 1)) are known. Pluronic F-127 (trade name, manufactured by BASF Wyandotte Chemicals Co.) in which polyethylene oxide is bonded to both ends of polypropylene as a polyalkylene oxide block copolymer ) Gels are being developed.
- the high-concentration aqueous solution of this pull-mouth nick F-127 becomes a hydrogel at about 20 ° C or higher, and becomes an aqueous solution at a lower temperature.
- a high The gel state can be obtained only by the concentration, and even if the temperature is higher than the gelation temperature at a high concentration of about 20 wt% or more, the gel will be dissolved by adding more water.
- the pull mouth nick F-127 has a relatively small molecular weight, exhibits a very high osmotic pressure in a gel state at a high concentration of about 20 wt% or more, and easily penetrates the cell membrane, so that cells and microorganisms could have a negative effect on
- the sol-gel transition temperature is high and is about 45 ° C or higher (N. Sarkar, J Appl. Polym. Science, 2_ ⁇ , 1073, 1979). Therefore, in the case of such an etherified senorose mouth, it is difficult to gel at body temperature (about 38 ° C.), so that it is usually difficult to apply it to the use of the present invention.
- a problem in the case of using a conventional polymer having a mouth-opening gel-forming property alone which has a sol-gel transition point in its aqueous solution and shows a sol state reversibly at a temperature lower than the transition temperature.
- the points are: 1) once gelled at a temperature higher than the sol-gel transition temperature, the gel is dissolved when water is further added; 2) the sol-gel transition temperature is higher than body temperature (about 38 ° C). And it is in a sol state in the body. 3) It is necessary to make the concentration of the polymer in the aqueous solution extremely high in order to gel.
- a plurality of polymer chains having a cloud point and a hydrophilic polymer chain block are combined, and an aqueous solution thereof has a sol-gel transition temperature, and a sol-gel transition. It has been found that a polymer that exhibits a sol state reversibly at a temperature lower than the temperature can be particularly suitably used as a hydrogel-forming polymer that forms the gelling component F.
- the solubility temperature coefficient for water is negative.
- polypropylene a copolymer of propylene oxide with another alkylene oxide, a poly N-substituted acrylamide derivative, a poly N —
- a polymer selected from the group consisting of substituted metaacrylamide derivatives, copolymers of N-substituted acrylamide derivatives and N-substituted metaacrylamide derivatives, polybutyl methyl ether, and partially acetylated polybutyl alcohol Is preferably used.
- the cloud point of the above polymer is higher than 4 ° C.
- the gelling component F (a plurality of particles having a cloud point) used in the present invention is used.
- the sol-gel transition temperature of the polymer chain (a compound in which a polymer chain and a hydrophilic polymer chain are bonded) is set to be higher than 4 ° C and 40 ° C or lower.
- the cloud point is measured, for example, by cooling an aqueous solution of about 1 wt% of the above-mentioned polymer (polymer chain having a cloud point) into a transparent and homogeneous solution, and then gradually increasing the temperature (temperature rising). At a rate of about l ° CZ min), the point at which the solution becomes cloudy for the first time is set as the cloud point.
- Poly N-substituted acrylamide derivatives and poly N monosubstituted methacrylamide derivatives that can be used in the present invention are listed below.
- the above polymer may be a homopolymer (homopolymer) or a copolymer of a monomer constituting the above polymer and another monomer.
- Other monomers constituting such a copolymer include hydrophilic monomers. Any of hydrophobic monomers can be used. In general, copolymerization with a hydrophilic monomer increases the cloud point of the product, and copolymerization with a hydrophobic monomer lowers the cloud point of the product. Accordingly, even by selecting these monomers to be copolymerized, a polymer having a desired cloud point (for example, a cloud point higher than 4 ° C and 40 ° C or lower) can be obtained. be able to.
- a desired cloud point for example, a cloud point higher than 4 ° C and 40 ° C or lower
- hydrophilic monomers examples include N—vinylpyrrolidone, vinylpyridine, acrylamide, methatalinoleamide, N—methylacrylyl amide, hydroxicetylmetarate, and hydroxicetila Acrylate, hydroxymethyl methacrylate, hydroxymethyl acrylate, acrylic acid having an acidic group, metaacrylic acid and salts thereof, vinyl snolefonic acid, styrene sulfonic acid, etc.
- N N-dimethylaminoethyl methacrylate having a basic group
- examples of the hydrophobic monomer include acrylate derivatives such as ethyl acrylate, methyl methacrylate, and glycidyl methacrylate, and methacrylate derivatives and N_ Examples include, but are not limited to, N-substituted alkyl methacrylamide derivatives such as n-butyl methacryloamide, vinyl chloride, acrylonitrile, styrene, and sulfuric acid butyl.
- hydrophilic polymer chains to be bound to the polymer chains having the above cloud point include collagen, gelatin, casein, albumin, methylcellulose, dextran, and polyethylene oxide.
- the method of bonding the polymer chain having a cloud point and the above-mentioned hydrophilic polymer chain is not particularly limited.
- a polymerizable functional group for example, an acryloyl group
- a combination of a polymer chain having a cloud point and the above-mentioned hydrophilic polymer chain includes a monomer that provides a polymer chain having a cloud point and a monomer that provides a hydrophilic polymer chain.
- the bonding between the polymer chain having a cloud point and the hydrophilic polymer chain is carried out by introducing a reactive group (for example, a hydroxyl group, an amino group, a hydroxyl group, a dissociate group, etc.) into both of them in advance.
- a reactive group for example, a hydroxyl group, an amino group, a hydroxyl group, a dissociate group, etc.
- both can be performed by bonding the both by a chemical reaction.
- a plurality of reactive functional groups are introduced into the hydrophilic polymer chain.
- the bond between the polypropylene polymer having a cloud point and the hydrophilic polymer chain can be formed by, for example, anion polymerization or cationic polymerization.
- a polymer chain copolymer in which polypropylene oxide and a “hydrophilic polymer chain” (for example, polyethylene oxide) are bonded can be obtained.
- Such a block copolymer is obtained by introducing a polymerizable group (for example, an acryloyl group) into the end of polypropylene oxide and then copolymerizing a monomer constituting a hydrophilic polymer chain. You can also get things Wear.
- a functional group capable of binding with a functional group for example, a hydroxyl group
- a functional group for example, a hydroxyl group
- a gelling component F can be obtained.
- hydrogel-forming material such as Pull Mouth Nick F-127 (trade name, manufactured by Asahi Denka Kogyo Co., Ltd.), in which polyethylene glycol is bonded to both ends of polypropylene glycol, may be linked.
- the gelling component F used in the present invention can be obtained.
- the gelling component F of the present invention is characterized in that, at a temperature lower than the cloud point, the above-mentioned “polymer chain having a cloud point” existing in the molecule is a hydrophilic polymer. Since both chains are water-soluble, they are completely dissolved in water and show a sol state. However, when the temperature of the aqueous solution of this polymer is heated to a temperature higher than the above cloud point, it is present in the molecule.
- the gelling component F of the present invention When heated to a temperature higher than the cloud point), it is water-soluble, so the gelling component F of the present invention has a crosslinked point in water at the hydrophobic association between polymer chains having a cloud point. It forms a hydrogel with a three-dimensional network structure.
- the temperature of the hide-mouth gel is again cooled to a temperature lower than the cloud point of the “polymer chain having a cloud point” existing in the molecule, the polymer chain having the cloud point becomes water-soluble, Crosslinking points due to the hydrophobic association are released, the gel structure of the mouth opening disappears, and the polymer of the present invention becomes a complete aqueous solution again.
- the sol-gel transition of the gelling component F of the present invention is based on, for example, a change in reversible hydrophilicity and hydrophobicity at the cloud point of a polymer chain having a cloud point existing in the molecule. Can have substantially complete reversibility in response to temperature changes.
- a larger amount 0.1 to 100% of the gel in volume ratio
- the gel does not dissolve even if water is added.
- Such properties of the polymer used in the present invention are achieved by the presence of two or more (multiple) polymer chains having a cloud point in the polymer.
- the ⁇ gelling mechanism S '' is preferably a chemical gelation.
- the “gelation mechanism S” is irreversible gelation.
- the polymer components constituting the gelling component F and the gelling component S may be the same or different.
- the gelling component S is preferably a material that undergoes chemical gelation and Z or irreversible gelation.
- the gelation mechanism of the gelling component S is not particularly limited as long as the above-mentioned condition of “slow gelation” is satisfied.
- gelation may occur at relatively low temperatures (eg, below 40 ° C) and in the presence of Z or moisture. It preferably contains a polymer capable of forming a gel.
- the gelling component S is composed of a gel-forming polymer and It is preferable to include at least a catalyst (preferably an enzyme) for gelling the molecule.
- a catalyst preferably an enzyme
- the above-mentioned gelation temperature, moisture conditions, and safety and toxicity issues are comprehensively considered.
- the gel-forming polymer it is preferable to use a biopolymer (and / or a derivative thereof) such as a protein, a glycoprotein and a polypeptide.
- Such a polymer substrate specifically reacts with the substrate and can be suitably used in combination with a catalyst (including an enzyme which is a biocatalyst) for gelling the polymer substrate.
- a catalyst including an enzyme which is a biocatalyst
- the gelation reaction of the component S is caused by a chemical reaction, particularly an enzymatic reaction, and the crosslinks preferably belong to a chemical gel formed by covalent bonds.
- the combination of a polymer substrate suitably usable in the present invention and a catalyst (for example, an enzyme) is not particularly limited as long as the above-mentioned condition of “slow gelation” is satisfied. In such a case, a combination of a polymer substrate and an enzyme as described below can be particularly preferably used.
- Transglutaminase is widely distributed in higher animals, fish and shellfish, and microorganisms, and is the ⁇ -carboxamide group of the glutamine (G in) residue in proteins and polypeptides. It is an enzyme that catalyzes the transfer reaction.
- ⁇ -amino group of a lysine (Lys) residue in a protein or polypeptide acts as an acyl receptor, ⁇ ( ⁇ -glutamyl) lysine (G-L Abbreviation), that is, a peptide bond is formed, and the proteins are cross-linked and gelled.
- the most typical example is plasma transglutaminase (factor XIII), an enzyme that G-L crosslinks fibrin produced by the action of thrombin and significantly improves thrombus stability.
- transglutaminase transglutaminase produced by microorganisms has become inexpensive. It is produced in large quantities and is used industrially for gelling protein foods.
- Suitable high molecular substrates include, for example, collagen, gelatin, myosin, fibrinogen, fibrin, casein, keratin, ⁇ -globulin, laminin, fibronectin, fibroblast growth factor ( FGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and the like.
- FGF fibroblast growth factor
- EGF epidermal growth factor
- VEGF vascular endothelial growth factor
- a preferred example of the gelling component S of the present invention includes the above-mentioned polymer substrate and a mixture of TGase or MTGase.
- the high molecular chain which is a component of the gelling component F of the present invention has collagen, gelatin and casei having a glutamine residue and a lysine residue.
- the gelling component F forms a chemical gel by TGase and MTGase, and plays a role of the gelling component S of the present invention. Therefore, in such a case, the gelling component F (including the polymer P) and the gelling component S (including the polymer P and the gelling catalyst Cat) share the polymer P as a component. Will be included.
- Sulfidolyloxidase is a macromolecule such as protein, glycoprotein, and polypeptide having a thiol group, such as collagen, gelatin, myosin, fibrinogen, fibrin, casein, and keratin. Specifically reacts with, albumin, ⁇ -globulin, laminin, fibronectin, insulin, etc. to form a disulfide bond within or between molecules to gel. . Therefore, in such a case, the gelling component S contains a mixture of the above-mentioned polymer substrate and sulfhydryloxidase.
- the hydrophilic polymer chain which is a component of the gelling component F of the present invention contains a protein having a thiol group, such as collagen, gelatin, casein, or albumin
- the S-S cross-linking enzyme is used.
- the gelling component F forms a chemical gel and plays the role of the gelling component S of the present invention. Therefore, in such a case, the gelling component F (including the polymer P) and the gelling component S (including the polymer P and the gelling catalyst Cat) form the common polymer P as a component. It is included as
- the gelling component S contains a mixture of the above-mentioned polymer substrate and thrombin.
- thermoreversible hide gel of the gelling type at the time of heating as the gelling component F of the present invention is a physical gel formed by a hydrophobic bond
- the hydrophobic binding force is usually used. Is most affected by changes in temperature, but less affected by changes in pH and salt concentration. Therefore, the aqueous solution of the above-mentioned gel-forming polymer having a sol-gel transition temperature lower than the body temperature (about 38 ° C) is easily in a sol state at a temperature lower than the sol-gel transition temperature and at a desired site in a living body. It can be injected and gels immediately at body temperature, that is, at a temperature higher than the sol-gel transition temperature, and can be stably placed at the site.
- the bridge structure is formed by a hydrophobic bond having a weak bonding force
- the cross-linked structure becomes unstable due to a slight temperature change or concentration change.
- mechanical strength For example, it is difficult for the gelling component F alone to be stably kept at the site for a long period of time due to its low water content.
- the gelling component S in the present invention is a mixed system of a polymer substrate such as a protein, glycoprotein and polypeptide and an enzyme which specifically reacts with the polymer substrate,
- a polymer substrate such as a protein, glycoprotein and polypeptide
- an enzyme which specifically reacts with the polymer substrate
- the concentration, the pH, the type of salt, and the concentration are determined under physiological conditions (for example, when the concentration is The reaction proceeds within a range of about 38 ° C, pH is in the neutral range, and the type and concentration of salt is within the same range as physiological saline or Ringer's solution), and a gel is formed.
- the concentration, PH, type of salt, concentration, etc. are not in the gelation reaction of the aqueous solution of the gelling component S, but in a sol state, and easily injected into the desired site in the organism.
- the gelling reaction of the gelling component S proceeds as the temperature, pH, kind and concentration of salt gradually change to physiological conditions at the site.
- the gelation reaction rate is extremely slow compared to the "fast" gelation reaction rate of the gelling component F. Therefore, it is extremely difficult to stably place only the gelling component S at a site in a living body. .
- an aqueous solution of the composition (II) is injected into a living body under physiological conditions in order to promote the gelling reaction of the gelling component S, during the preparation of the aqueous solution or injection into the living body During this time, the gelation reaction proceeds, and it becomes extremely difficult to inject into a desired site in a living body. That is, when only the gelling component S is used, it is extremely difficult to optimally control the speed of the gelling reaction.
- the cross-linked structure of the gelling component S is formed by covalent bonds, it has excellent stability against changes in external factors such as temperature and concentration and excellent mechanical strength, so that it can be placed at a desired site for a long time. It is possible to place it stably.
- the gelling component F and the gelling component S are combined to form a gel. and u constitute sex composition C.
- the aqueous solution (sol state) of the gelling composition C is not controlled by temperature, pH, salt type and concentration.
- the temperature of the gelling composition C becomes higher than the sol-gel transition temperature due to body temperature.
- the temperature becomes high, and the gelling composition C gels by first gelling the gelling component F.
- the enzymatic reaction of the gelling component S proceeds, and a chemical gel of the gelling component S is formed.
- a gel stabilized by the gelling composition C is formed.
- the aqueous solution (sol state) of the gelling composition C of the present invention is subjected to body temperature (approximately). It is preferable to prepare at a temperature significantly lower than (38 ° C) (a temperature lower than the sol-gel transition temperature of the gelling component F) and administer it to the living body.
- a temperature significantly lower than (38 ° C) a temperature lower than the sol-gel transition temperature of the gelling component F
- an enzymatic reaction proceeds to contribute to stabilization of the gelling composition C of the present invention.
- the temperature should be lowered sufficiently below the body temperature during preparation or injection into the body, or the pH should be adjusted to 5 or less. By setting the value to less than or equal to 10 or more, the progress of the crosslinking reaction of fibrinogen by thrombin can be suppressed.
- the temperature or pH of the composition gradually changes to physiological conditions in a living body, fibrinogen changes to cross-linked fibrin, which contributes to stabilization of the gelling composition C of the present invention.
- the gellable composition of the present invention contains at least a polymer component and a gelling agent for gelling the polymer component, but may contain other components as necessary. Is also good.
- the type and number of such components are also good.
- the content and the like are not particularly limited as long as the balance between the fast gelling F and the relatively slow gelling S of the composition is not substantially inhibited.
- Such “other components” include, for example, drugs, bioactive substances, and Z or cells.
- the above agents include, for example, anticancer agents, antibacterial agents, anticoagulants and the like.
- an effect corresponding to the action of the drug can be obtained.
- physiologically active substance examples include FGF, EGF, VEGF, and the like.
- FGF FGF
- EGF EGF
- VEGF vascular endothelial growth factor
- the above cells include bone marrow cells, fibroblasts, vascular endothelial cells and the like.
- effects such as healing promoting properties can be obtained.
- the present invention will be described more specifically with reference to Examples.
- Polypropylene oxide polyethylene oxide copolymer (Propylene oxide ethylene oxide average polymerization degree is about 60 Z180, manufactured by Asahi Denka Kogyo Co., Ltd .: Pull mouth nick F—127) 10 g was dissolved in 30 ml of dry chloroform and mixed with hexagonal pentoxide. 0.13 g of Chilledyne Sociate was added, and the mixture was reacted under boiling point reflux for 6 hours. After distilling off the solvent under reduced pressure, the residue was dissolved in distilled water and subjected to ultrafiltration with a molecular weight cut off of 30,000 to separate a high molecular weight polymer and a low molecular weight polymer. The obtained aqueous solution was frozen to obtain an F-127 high polymer and an F-127 low polymer.
- the F-127 high polymer (TGP-1) obtained above was dissolved in distilled water at 4 ° C and at a concentration of 8% by mass.
- this aqueous solution was gradually heated, the viscosity gradually increased from 21 ° C, and solidified at about 27 ° C to form a hydrogel.
- the gel returned to an aqueous solution at 21 ° C. This change was observed reversibly and repeatedly.
- the above F-127 low polymer dissolved in distilled water at a concentration of 8% by mass did not gel at all even when heated to 60 ° C or more.
- a 10% aqueous solution of alkali-treated gelatin (manufactured by Nitta Gelatin Co., Ltd.) obtained from adult cattle bone was prepared, and the F-127 high polymer (TGP-1) obtained above was prepared in the aqueous solution.
- TGP-1 high polymer obtained above was prepared in the aqueous solution.
- MT Gase transglutaminase
- aqueous solution (I) of the gelling composition C prepared as the aqueous solution (I) of the product C was injected into a glass test tube having an inner diameter of about 12 mm at about 10 ° C. Thereafter, when the test tube is immersed in a constant temperature water bath at a temperature of about 38 ° C, the aqueous solution (I) is immediately gelled (when the temperature of the aqueous solution rises above the sol-gel temperature of TGP-1). It has become. The gelation of the aqueous solution was confirmed by the fact that the aqueous solution did not flow when the test tube containing the aqueous solution was turned upside down.
- test tube containing the aqueous solution (I) Immerse the test tube containing the aqueous solution (I) in a constant temperature water bath at about 38 ° C. Approximately 30 minutes after the immersion, the test tube containing the gelled aqueous solution (I) was immediately immersed in a thermostatic water bath at a temperature lower than the sol-gel transition temperature of TGP-1 at approximately 10 When the temperature of the aqueous solution dropped to a temperature lower than the Zolgel transition temperature of TGP-1), it became sol.
- a test tube containing the gelled aqueous solution (I) was immersed in a constant temperature water bath at about 38, and after about 6 hours, the test tube was cooled to a temperature lower than the TGP-1 Zolgel transition temperature. Even when immersed in a constant temperature water bath at about 10 ° C, no sol was formed in the gelled aqueous solution (I).
- the aqueous solution of the gelling composition C (I) of the present invention was formed into a sol at a temperature lower than the sol-gel transition temperature of the gelling component F (TGP-1).
- TGP-1 could be readily administered in vivo, and when administered in vivo, TGP-1 gelled immediately and could be placed at the site of administration.
- the gelling composition C (I) is characterized in that the gelatin of the gelling component S gradually gels at body temperature (about 38 ° C) by the enzymatic reaction of MTGase, resulting in the present invention.
- the stability of the gelling composition C (I) of the invention was remarkably improved.
- a 10% aqueous solution of alkali-treated gelatin was prepared in the same manner as in Example 1, and the F-127 high polymer (TGP-1) synthesized in Example 1 was reduced to about 10% in the aqueous solution.
- TGP-1 was dissolved under stirring at a temperature lower than the sol-gel transition temperature of about 10 ° C.
- sulfidyl oxidase is dissolved in the aqueous solution under stirring at about 10 ° C. so that the enzyme concentration becomes about 10 units nom 1, and the aqueous solution of the gelling composition C of the present invention (II) was prepared.
- the test tube containing the gelled aqueous solution (II) was taken from the TGP-1 sol-gel transition temperature.
- the test tube containing the gelled aqueous solution (II) was taken from the TGP-1 sol-gel transition temperature.
- a constant temperature water bath at a low temperature of about 10 ° C when the temperature of the aqueous solution dropped to a temperature lower than the sol-gel transition temperature of TGP-1, it turned into a sol.
- test tube containing the gelled aqueous solution (II) is immersed in a constant temperature water bath at about 38 ° C, about 10 hours later, the test tube is lower than the sol-gel transition temperature of TGP-1. Even when immersed in a constant temperature water bath at a temperature of about 10 ° C, no sol was formed in the gelled aqueous solution (II).
- the aqueous solution of the gelling composition C (II) of the present invention is sol-formed at a temperature lower than the sol-gel transition temperature of the gelling component F (TGP-1), and is in a solution state. It could be easily administered into the body, and upon administration into the living body, TGP-1 immediately gelled and could be placed at the site of administration.
- the composition C (II) is characterized in that the gelatin of the gelling component S is gradually gelled at body temperature (about 38 ° C.) by the enzymatic reaction of sulfhydryl oxidase, whereby the composition of the present invention is obtained.
- the stability of the gelling composition C (II) was remarkably improved.
- Shifibrinogen manufactured by Wako Pure Chemical Industries, Ltd.
- physiological saline having a pH adjusted to about 5 to a concentration of about 20 g Zl
- F— synthesized in Example 1 was dissolved.
- the 127 high polymer (TGP-1) was dissolved under stirring at about 10 ° C., which is lower than the sol-gel transition temperature of TGP-1, so as to have a concentration of about 10%.
- dicitrombin was dissolved in the aqueous solution at 10 ° C. so that the concentration became about 1.0 unit Zm 1 and the present invention was carried out.
- An aqueous solution (III) of the gelling composition C was prepared.
- aqueous solution ( ⁇ ) After injecting about 10 ml of the aqueous solution ( ⁇ ) at about 10 ° C into a plastic jar having an inner diameter of 80 ⁇ , place the dish in a heat incubator at about 38 ° C. And the aqueous solution (III) gelled immediately (when the temperature of the aqueous solution rose to a temperature higher than the sol-gel temperature of TGP-1). The solution (III) was turned into a sol immediately after it was placed in a thermostat at 38 ° C and the dish containing the gelled aqueous solution (III) was placed in a refrigerator at about 6 ° C.
- the aqueous solution of the gelling composition C (III) of the present invention is at a temperature lower than the sol-gel transition temperature of the gelling component F (TGP-1) and when the pH of the aqueous solution is about 5, It was in a sol state and could be easily injected into a living body.
- TGP-1 When administered into a living body, TGP-1 immediately gelled and could be placed at the site to be administered.
- body temperature about 38 ° C.
- thrombin converts fibrinogen into fibrin, and the gelling composition C of the present invention
- the stability of (III) was significantly improved. Industrial applicability
- a gelling composition comprising at least a polymer component and a gelling agent for gelling the polymer component;
- a gelling composition characterized by exhibiting at least two types of gelation with relatively slow gelation S is provided.
- a gelling composition further comprising at least a polymer component and a gelling agent for gelling the polymer component;
- a gelling composition further comprising at least a polymer component and a gelling agent for gelling the polymer component; a relatively fast gelling F;
- a gelling composition is provided, which exhibits at least two types of gelling with slow gelling S, and has a different mechanism of gelling F and S.
- a reversible and relatively fast gelling F, and an irreversible and relatively slow gel are further contained, at least, a polymer component and a gelling agent for gelling the polymer component.
- the present invention provides a gelling composition characterized by exhibiting at least two types of gelation with the compound S.
- the gellable composition of the present invention has good parameters of short-term adhesive strength (for example, instant adhesive strength) and long-term adhesive strength (for example, long-lasting adhesive strength). Since the balance can be easily realized, the present invention can be applied to a field in which these balances are required (for example, adhesion in a fluid or a liquid, repair of a fluid transfer pipe, and the like) without any particular limitation.
- the gelling composition of the present invention When the gelling composition of the present invention is applied to, for example, the medical field, the gelling composition is injected into a living body, for example, in the form of an aqueous solution (sol), and rapidly gelled. It is possible to stay. In this case, by gradually gelling the gelling composition in a living body, it becomes possible to improve the mechanical strength and to remarkably improve the stability in the living body. Therefore, in this case, a so-called “instant adhesive” in vivo that also has stability (for example, an intravascular embolic agent, a hemostatic agent, a bioadhesive, an anti-adhesion agent, a wound covering agent, a drug delivery agent) It can be widely and suitably used
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01932200A EP1288264A4 (en) | 2000-05-22 | 2001-05-22 | YELLOW COMPOSITIONS |
CA002410038A CA2410038A1 (en) | 2000-05-22 | 2001-05-22 | Gelling composition |
US10/296,299 US20030109587A1 (en) | 2000-05-22 | 2001-05-22 | Gelling composition |
AU2001258801A AU2001258801A1 (en) | 2000-05-22 | 2001-05-22 | Gelling composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-154410 | 2000-05-22 | ||
JP2000154410A JP2001329183A (ja) | 2000-05-22 | 2000-05-22 | ゲル化性組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001090252A1 true WO2001090252A1 (en) | 2001-11-29 |
Family
ID=18659512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/004277 WO2001090252A1 (en) | 2000-05-22 | 2001-05-22 | Gelling composition |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030109587A1 (ja) |
EP (1) | EP1288264A4 (ja) |
JP (1) | JP2001329183A (ja) |
AU (1) | AU2001258801A1 (ja) |
CA (1) | CA2410038A1 (ja) |
WO (1) | WO2001090252A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7618937B2 (en) * | 2001-07-20 | 2009-11-17 | Northwestern University | Peptidomimetic polymers for antifouling surfaces |
US7858679B2 (en) * | 2001-07-20 | 2010-12-28 | Northwestern University | Polymeric compositions and related methods of use |
US8815793B2 (en) * | 2001-07-20 | 2014-08-26 | Northwestern University | Polymeric compositions and related methods of use |
US8911831B2 (en) * | 2002-07-19 | 2014-12-16 | Northwestern University | Surface independent, surface-modifying, multifunctional coatings and applications thereof |
EP1562630A4 (en) * | 2002-10-31 | 2009-02-18 | Univ Northwestern | INJECTABLE BIOADHûSIVE POLYMERS HYDROGELES AND RELEVANT PROCESSES FOR ENZYMATIC PRODUCTION |
JP2004283371A (ja) * | 2003-03-20 | 2004-10-14 | Nagoya Industrial Science Research Inst | 医用材料 |
MXPA05010002A (es) * | 2003-03-24 | 2006-03-10 | Biosphere Medical Inc | Embolizacion temporal utilizando polimeros termosensibles inversos. |
US7700086B2 (en) | 2003-11-06 | 2010-04-20 | Pluromed, Inc. | Internal clamp for surgical procedures |
US8920827B2 (en) | 2005-10-21 | 2014-12-30 | Wake Forest University Health Sciences | Keratin bioceramic compositions |
US8062282B2 (en) * | 2006-02-13 | 2011-11-22 | Fossa Medical, Inc. | Methods and apparatus for temporarily occluding body openings |
US7732539B2 (en) * | 2006-02-16 | 2010-06-08 | National Science Foundation | Modified acrylic block copolymers for hydrogels and pressure sensitive wet adhesives |
JP5597836B2 (ja) | 2006-08-04 | 2014-10-01 | ケンジー ナッシュ コーポレイション | バイオミメティック化合物およびその合成方法 |
WO2008091386A2 (en) * | 2006-08-04 | 2008-07-31 | Northwestern University | Biomimetic modular adhesive complex: material, methods and applications therefore |
BRPI0718328A2 (pt) | 2006-12-15 | 2011-10-11 | Lifebond Ltd | composição, curativo hemostático e dispositivo médico para a inserção em um corpo de um ser humano ou de um mamìfero inferior |
WO2008089032A1 (en) * | 2007-01-11 | 2008-07-24 | Northwestern University | Fouling resistant coatings and methods of making same |
US8673286B2 (en) | 2007-04-09 | 2014-03-18 | Northwestern University | DOPA-functionalized, branched, poly(aklylene oxide) adhesives |
US8383092B2 (en) | 2007-02-16 | 2013-02-26 | Knc Ner Acquisition Sub, Inc. | Bioadhesive constructs |
BRPI0807558A2 (pt) * | 2007-02-22 | 2014-07-01 | Pluromed Inc | Uso de polímeros termosensíveis reversos para controlar o fluxo de fluido biológico subsequente a um procedimento médico |
US8557583B2 (en) | 2007-03-15 | 2013-10-15 | Dai Nippon Printing Co., Ltd. | Cell culture support and manufacture thereof |
CN104031393B (zh) | 2008-06-18 | 2017-08-01 | 生命连结有限公司 | 改进的交联组合物 |
WO2009153751A2 (en) * | 2008-06-18 | 2009-12-23 | Lifebond Ltd | A method for enzymatic cross-linking of a protein |
US20110130465A1 (en) * | 2009-12-01 | 2011-06-02 | Nerites Corporation | Coatings for prevention of biofilms |
DK2515957T3 (en) | 2009-12-22 | 2015-11-09 | Lifebond Ltd | CHANGE OF ENZYMATIC CIRCULATORS FOR MANAGEMENT OF CHARACTERISTICS BY CIRCUIT MATRIX |
US8961544B2 (en) | 2010-08-05 | 2015-02-24 | Lifebond Ltd. | Dry composition wound dressings and adhesives comprising gelatin and transglutaminase in a cross-linked matrix |
CA2817215C (en) | 2010-11-09 | 2017-05-09 | Knc Ner Acquisition Sub, Inc. | Adhesive compounds for use in hernia repair |
EP2640408B1 (en) | 2010-11-17 | 2016-05-25 | Wake Forest University Health Sciences | Keratin compositions for treatment of bone deficiency or injury |
JP2014515052A (ja) * | 2011-03-28 | 2014-06-26 | ヒタチ ケミカル リサーチ センター インコーポレイテッド | 溶解性を向上させたネットワーク共役ポリマー |
AU2012296477B2 (en) | 2011-08-17 | 2017-04-27 | Keratin Biosciences, Inc. | Methods for extracting keratin proteins |
WO2013025941A1 (en) | 2011-08-17 | 2013-02-21 | Keranetics Llc | Low protein percentage gelling compositions |
US9827245B2 (en) | 2013-03-15 | 2017-11-28 | KeraNetics, LLC | Keratin compositions comprising halofuginone |
US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57164064A (en) * | 1981-04-02 | 1982-10-08 | Toray Industries | Therapeutic hydrogel |
JPS63230041A (ja) * | 1987-03-18 | 1988-09-26 | Meiji Milk Prod Co Ltd | 異種ゲルの混在するゲル化食品の製造方法 |
JPH05255119A (ja) * | 1992-02-25 | 1993-10-05 | W R Grace & Co | ドラッグキャリアー |
JPH11169703A (ja) * | 1997-12-17 | 1999-06-29 | M & M Kenkyusho:Kk | 熱可逆ハイドロゲル形成性組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5000955A (en) * | 1988-07-29 | 1991-03-19 | Tyndale Plains-Hunter Ltd. | Thermally reversible polyurethane hydrogels and cosmetic, biological and medical uses |
US4964461A (en) * | 1989-11-03 | 1990-10-23 | Mobil Oil Corporation | Programmed gelation of polymers using melamine resins |
SE9003712L (sv) * | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner |
DE4140192C2 (de) * | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
US5702717A (en) * | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
US6162241A (en) * | 1997-08-06 | 2000-12-19 | Focal, Inc. | Hemostatic tissue sealants |
AU2584199A (en) * | 1999-02-05 | 2000-08-25 | Regents Of The University Of California, The | Thermo-reversible polymer for intralumenal implant |
-
2000
- 2000-05-22 JP JP2000154410A patent/JP2001329183A/ja active Pending
-
2001
- 2001-05-22 US US10/296,299 patent/US20030109587A1/en not_active Abandoned
- 2001-05-22 WO PCT/JP2001/004277 patent/WO2001090252A1/ja not_active Application Discontinuation
- 2001-05-22 AU AU2001258801A patent/AU2001258801A1/en not_active Abandoned
- 2001-05-22 EP EP01932200A patent/EP1288264A4/en not_active Withdrawn
- 2001-05-22 CA CA002410038A patent/CA2410038A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57164064A (en) * | 1981-04-02 | 1982-10-08 | Toray Industries | Therapeutic hydrogel |
JPS63230041A (ja) * | 1987-03-18 | 1988-09-26 | Meiji Milk Prod Co Ltd | 異種ゲルの混在するゲル化食品の製造方法 |
JPH05255119A (ja) * | 1992-02-25 | 1993-10-05 | W R Grace & Co | ドラッグキャリアー |
JPH11169703A (ja) * | 1997-12-17 | 1999-06-29 | M & M Kenkyusho:Kk | 熱可逆ハイドロゲル形成性組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1288264A4 * |
Also Published As
Publication number | Publication date |
---|---|
JP2001329183A (ja) | 2001-11-27 |
AU2001258801A1 (en) | 2001-12-03 |
US20030109587A1 (en) | 2003-06-12 |
CA2410038A1 (en) | 2002-11-20 |
EP1288264A1 (en) | 2003-03-05 |
EP1288264A4 (en) | 2004-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001090252A1 (en) | Gelling composition | |
Dompé et al. | Underwater adhesion of multiresponsive complex coacervates | |
Balakrishnan et al. | A novel injectable tissue adhesive based on oxidized dextran and chitosan | |
Lawrence et al. | Ionically cross-linked poly (allylamine) as a stimulus-responsive underwater adhesive: Ionic strength and pH effects | |
US9694101B2 (en) | Flowable collagen-based hemostat and methods of use | |
Lee et al. | In-situ injectable physically and chemically gelling NIPAAm-based copolymer system for embolization | |
Hoffman | Conventional and environmentally-sensitive hydrogels for medical and industrial uses: a review paper | |
CN108976317A (zh) | 一种壳聚糖生物大分子及其制备方法和应用 | |
Wang et al. | A comparison of chitosan and collagen sponges as hemostatic dressings | |
US20050002893A1 (en) | Composition consisting of a polymer containing amino groups and an aldehyde containing at least three aldehyde groups | |
US20050271727A1 (en) | Biodegradable and biocompatible crosslinked polymer hydrogel prepared from PVA and/or PEG macromer mixtures | |
CN111234268B (zh) | 多功能特异性生物粘合水凝胶、制备方法及其应用 | |
RU2770445C2 (ru) | Композиция предшественника гидрогеля и её применение | |
WO2006080523A1 (ja) | 自己分解性を有する医療用2液反応型接着剤、及び医療用樹脂 | |
CA2299336A1 (en) | Hemostatic tissue sealants | |
Micic et al. | Network parameters and biocompatibility of p (2-hydroxyethyl methacrylate/itaconic acid/oligo (ethylene glycol) acrylate) dual-responsive hydrogels | |
KR100492652B1 (ko) | 하이드로겔용 조성물, 하이드로겔 및 그 용도 | |
Yoshioka et al. | Thermoreversible gelation on cooling and on heating of an aqueous gelatin–poly (N‐isopropylacrylamide) conjugate | |
JP2022023994A (ja) | タンパク質-ポリマー・コンジュゲートを含む有機溶媒不含組成物および該組成物の使用 | |
CN113289052B (zh) | 一种可控交联、降解的材料及其应用 | |
Bajpai et al. | Preparation and characterization of macroporous poly (2‐hydroxyethyl methacrylate)‐based biomaterials: Water sorption property and in vitro blood compatibility | |
US20120009242A1 (en) | Blood coagulation inducing polymer hydrogel | |
US20210170038A1 (en) | Biocampatible and Biodegradable Anionic Hydrogel System | |
JPH11169703A (ja) | 熱可逆ハイドロゲル形成性組成物 | |
JP2018123275A (ja) | 細胞接着防止剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2410038 Country of ref document: CA Ref document number: 10296299 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001932200 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001932200 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001932200 Country of ref document: EP |